Nowacka-Cieciura E, Perkowska-Ptasińska A, Sulikowska-Rowińska A, Cieciura T, Wazna E, Durlik M
Department of Transplantation Medicine and Nephrology, Transplantation Institute, Warsaw Medical University, Warsaw, Poland.
Transplant Proc. 2009 Jan-Feb;41(1):441-5. doi: 10.1016/j.transproceed.2008.09.058.
Conversion from calcineurin inhibitors (CNI) to proliferation signal inhibitors (PSI), such as sirolimus or everolimus (EV), may improve the course of chronic allograft nephropathy. Herein we have presented a case of a kidney recipient with chronic cyclosporine (CsA) nephrotoxicity who was converted from CsA to EV at 5.5 years posttransplantation. There were no significant changes in immunofluorescence (IFL) or in electron microscopy (EM) in the preconversion biopsy. Two months after conversion, proteinuria and creatinine increased. The biopsy showed focal, segmental necrosis of the glomerular tuft with the formation of segmental cellular crescents and increased endocapillary cellularity. IFL showed granular deposits of IgG, IgM, and C3 mostly along the capillary walls; it was negative for C4d. EM revealed electron-dense deposits within the glomerular basement membrane (GBM) and in the subendothelial region with significant reduction in the capillary lumina due to GBM reduplication and widening of lamina rara interna with the formation of fibrillary structures therein: focal, segmental glomerulosclerosis. EV was withdrawn and we administered tacrolimus and steroid pulses with improvement. Five months after the withdrawal of EV, a third graft biopsy showed remission of the necrotizing glomerulonephritis. However, the patient demanded dialysis at 17 months after conversion to EV. We concluded that necrotizing glomerulonephritis with immune complex deposition in a renal allograft was possibly induced by late conversion from CNI to EV. Reconversion to CNI may be recommended in cases of PSI-associated posttransplantation glomerulonephritis but the long-term prognosis is uncertain.
从钙调神经磷酸酶抑制剂(CNI)转换为增殖信号抑制剂(PSI),如西罗莫司或依维莫司(EV),可能会改善慢性移植肾肾病的病程。在此,我们报告了一例肾移植受者,该患者患有慢性环孢素(CsA)肾毒性,在移植后5.5年从CsA转换为EV。转换前活检的免疫荧光(IFL)或电子显微镜(EM)检查无显著变化。转换后两个月,蛋白尿和肌酐水平升高。活检显示肾小球毛细血管袢局灶性、节段性坏死,伴有节段性细胞性新月体形成和毛细血管内细胞增多。IFL显示IgG、IgM和C3颗粒状沉积物主要沿毛细血管壁分布;C4d呈阴性。EM显示肾小球基底膜(GBM)内和内皮下区域有电子致密沉积物,由于GBM重复和内疏松层增宽并在其中形成纤维状结构,毛细血管腔显著减小:局灶性、节段性肾小球硬化。停用EV后,我们给予他克莫司和类固醇冲击治疗,病情有所改善。停用EV五个月后,第三次移植肾活检显示坏死性肾小球肾炎缓解。然而,该患者在转换为EV后17个月需要透析。我们得出结论,肾移植中伴有免疫复合物沉积的坏死性肾小球肾炎可能是由从CNI晚期转换为EV所致。对于与PSI相关的移植后肾小球肾炎病例,可能建议重新转换为CNI,但长期预后尚不确定。